These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33305681)

  • 21. Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer.
    D'Andrea D; Soria F; Abufaraj M; Pones M; Gontero P; Machado AT; Waksman R; Enikeev DV; Glybochko PV; Adonias SP; Nahas WC; Shariat SF; Chade DC
    Clin Genitourin Cancer; 2020 Feb; 18(1):20-25.e2. PubMed ID: 31786120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
    Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contemporary Treatment Patterns for Non-muscle-invasive Bladder Cancer: Has the Use of Radical Cystectomy Changed in the BCG Shortage Era?
    Tully KH; Cole AP; Krimphove MJ; Friedlander DF; Mossanen M; Herzog P; Noldus J; Sonpavde GP; Trinh QD
    Urology; 2021 Jan; 147():199-204. PubMed ID: 32805294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
    Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
    Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer.
    Brake M; Loertzer H; Horsch R; Keller H
    Urology; 2000 May; 55(5):673-8. PubMed ID: 10792077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The association between BCG treatment in patients with bladder cancer and subsequent risk of developing Alzheimer and other dementia.-A Swedish nationwide cohort study from 1997 to 2019.
    Wang E; Hagberg O; Malmström PU
    PLoS One; 2023; 18(12):e0292174. PubMed ID: 38096211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Timing of Radical Cystectomy for bacillus Calmette-Guérin Failure: Comparison of Outcomes and Risk Factors for Prognosis.
    Haas CR; Barlow LJ; Badalato GM; DeCastro GJ; Benson MC; McKiernan JM
    J Urol; 2016 Jun; 195(6):1704-9. PubMed ID: 26807928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIVEC as an alternative option in non-muscle-invasive bladder cancer: Experiences from a high-volume center.
    Kastner L; Rieger C; Pfister D; Schmautz M; Storz E; Heidenreich A
    Urol Oncol; 2024 Aug; 42(8):245.e19-245.e26. PubMed ID: 38653592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study.
    Oughton JB; Poad H; Twiddy M; Collinson M; Hiley V; Gordon K; Johnson M; Jain S; Noon AP; Chahal R; Simms M; Dooldeniya M; Koenig P; Goodwin L; Brown JM; Catto JWF;
    BMJ Open; 2017 Aug; 7(8):e017913. PubMed ID: 28801444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Swedish National Registry of Urinary Bladder Cancer: No difference in relative survival over time despite more aggressive treatment.
    Jahnson S; Hosseini Aliabad A; Holmäng S; Jancke G; Liedberg F; Ljungberg B; Malmström PU; Rosell J
    Scand J Urol; 2016; 50(1):14-20. PubMed ID: 26382667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study.
    Miyake M; Iida K; Nishimura N; Miyamoto T; Fujimoto K; Tomida R; Matsumoto K; Numakura K; Inokuchi J; Morizane S; Yoneyama T; Matsumura Y; Abe T; Inoue M; Yamada T; Terada N; Hirao S; Uemura M; Matsushita Y; Taoka R; Kobayashi T; Kojima T; Matsui Y; Kitamura H; Nishiyama H;
    BMC Cancer; 2021 Mar; 21(1):266. PubMed ID: 33706705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up.
    Hurle R; Losa A; Manzetti A; Lembo A
    Urology; 1999 Aug; 54(2):258-63. PubMed ID: 10443721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer.
    Moussa M; Papatsoris AG; Dellis A; Abou Chakra M; Saad W
    Expert Rev Anticancer Ther; 2020 Nov; 20(11):965-983. PubMed ID: 32915676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of time to second transurethral resection on oncological outcomes of patients with high-grade T1 bladder cancer treated with intravesical Bacillus Calmette-Guerin.
    Calò B; Falagario U; Sanguedolce F; Veccia A; Chirico M; Carvalho-Diaz E; Mota P; Lima E; Autorino R; Carrieri G; Cormio L
    World J Urol; 2020 Dec; 38(12):3161-3167. PubMed ID: 32062805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical study of carcinoma in situ of the urinary bladder].
    Harada Y; Seguchi T; Nonomura N; Kojima Y; Miki T; Okuyama A
    Nihon Hinyokika Gakkai Zasshi; 1998 Aug; 89(8):693-7. PubMed ID: 9780653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Definitive BCG immunotherapy versus radical cystectomy in intermediate or high-risk nonmuscle invasive bladder cancer patients: A retrospective study.
    Jian X; Shen M; Liao G
    Medicine (Baltimore); 2019 Sep; 98(36):e16873. PubMed ID: 31490371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The influence over the long-term prognosis of BCG therapy and the surgical treatment in superficial bladder cancer treatment].
    Higashi S; Matsui Y; Takahashi T; Nishiyama H; Ito N; Yamamoto S; Kamoto T; Ogawa O
    Hinyokika Kiyo; 2005 Aug; 51(8):529-31. PubMed ID: 16164268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer.
    Balakrishnan AS; Washington SL; Meng MV; Porten SP
    Clin Genitourin Cancer; 2019 Jun; 17(3):e461-e471. PubMed ID: 30799130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.